现有数据支持进一步评估在研反义药物 OT-101（又名 trabedersen）作为靶向 TGFB2 -的治疗策略，用于胰腺导管腺癌的疗效。 圣地亚哥，加利福尼亚州, July 19, 2025 (GLOBE NEWSWIRE) -- Sapu Biosciences, LLC (Sapu)，是 GMP Biotechnology Limited（简称 GMP Bio）的全资子公司，与临床-阶段生物制药公司 Oncotelic Therapeutics, Inc.（OTCQB: OTLC，简称 Oncotelic）合作，后者专注于开发癌症及罕见疾病的-靶向 RNA 和小-分子治疗。今日，双方重点介绍了新发表的转化研究，该研究评估了 TGFB2 表达水平及其启动子甲基化作为胰腺导管腺癌（PDAC）潜在预后标志物的情况。 该文章题为《TGFB2 表达和甲基化预测胰腺导管腺癌患者的总生存期》，发表于《国际分子科学杂志》(IJMS)。 Sapu 相关研究员参与其中。 查看文章： DOI 10.3390/ijms26136357（可通过 IJMS 开放获取）。 研究重点 OT-101 P001 PDAC -研究的临床数 ...

Core Insights - Sapu Biosciences, in collaboration with Oncotelic Therapeutics, has published new research indicating that TGFB2 expression and promoter methylation may serve as prognostic markers in pancreatic ductal adenocarcinoma (PDAC) [1][2] Group 1: Research Findings - The study published in the International Journal of Molecular Sciences highlights that targeting TGFB2 warrants further evaluation, particularly in younger PDAC patients [1][2] - Clinical data from the OT-101 P001 PDAC study shows that in a subset of younger patients with low IL-6, the median overall survival (OS) was 12.7 months [2] - High TGFB2 expression correlates with significantly reduced OS in patients under 65, with median OS of 17.9 months for high TGFB2 expression compared to 66.9 months for low [2] Group 2: Clinical Implications - Elevated TGFB2 methylation is associated with improved survival in younger patients, with median OS of 66.9 months for high methylation versus 17.9 months for low methylation [2] - The findings suggest that TGFB2 is not merely a biomarker but a critical factor delineating a younger subset of pancreatic cancer patients who experience poorer survival outcomes [2]

Core Insights - Oncotelic Therapeutics is advancing the evaluation of OT-101, an investigational antisense oligonucleotide targeting TGFB2, as a potential treatment for pancreatic ductal adenocarcinoma (PDAC) [1][5] - New research indicates that TGFB2 expression and methylation may serve as prognostic markers for overall survival in PDAC patients, particularly in younger cohorts [1][2][3] Company Overview - Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing RNA-targeted and small-molecule therapeutics for cancer and rare diseases [1][6] - The company has a 45% ownership interest in Sapu Biosciences, which contributed to the recent research publication [1] Research Findings - The study published in the International Journal of Molecular Sciences highlights that high TGFB2 expression correlates with reduced overall survival in patients under 65 years old, with median overall survival of 17.9 months for high TGFB2 expression compared to 66.9 months for low expression [3] - Elevated TGFB2 methylation is associated with improved survival in younger patients, with median overall survival of 66.9 months for high methylation versus 17.9 months for low methylation [3] - Clinical data from the OT-101 P001 PDAC study suggests that targeting TGFB2 is particularly beneficial for younger patients, with a median overall survival of 12.7 months in a treated subset characterized by low IL-6 [2] Market Context - The incidence of PDAC is increasing among younger adults, with approximately 4% annual growth in the 15-34 age bracket, while the five-year survival rate for all PDAC patients is only around 12% [4] - The findings underscore the need for targeted therapies like OT-101 to address the grim outcomes faced by younger PDAC patients [4]

Core Insights - Oncotelic Therapeutics has published a peer-reviewed research article identifying TGFB2 gene methylation as a positive prognostic biomarker for pancreatic ductal adenocarcinoma (PDAC) [1][2] - The study highlights the potential of TGFB2 methylation to improve overall survival in patients with low CD8+ T-cell infiltration [2][3] Group 1: Research Findings - PDAC is characterized as one of the most lethal cancers with limited treatment options, primarily relying on cytotoxic regimens like FOLFIRINOX [2] - High TGFB2 methylation combined with low expression of immune markers such as CD3D, LCK, and HLA-DRA correlates with a median overall survival exceeding 50 months [3] - The study emphasizes the need to profile TGFB1, TGFB2, and TGFB3 methylation to better understand tumor immune status and select candidates for immunotherapy in resistant "cold" tumors [4] Group 2: Company Commentary - Dr. Sanjive Qazi, the lead author, stated that the discovery enhances understanding of the TGFB gene complex in PDAC, particularly in immunologically cold tumors, supporting further clinical development of OT-101 [5] - Scott Myers highlighted the role of the AI-powered chatbot platform PDAOAI in accelerating scientific discovery through literature mining and analysis [5] - Dr. Michael Potts noted that large language models like PDAOAI are transforming the identification and interpretation of biomedical insights [5] Group 3: Company Background - Oncotelic Therapeutics, originally formed as OXiGENE, Inc. in 1988, has undergone several name changes and is focused on oncology drug development, particularly for rare pediatric cancers [7] - The company has a 45% stake in GMP Biotechnology Limited, which is involved in the development of therapies for various cancers, including Diffuse Intrinsic Pontine Glioma (DIPG) and Acute Myeloid Leukemia (AML) [7] - Oncotelic also acquired PointR Data Inc. to build an AI-driven biotechnology company, further expanding its capabilities in drug development [7]